Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study

Population Health Metrics

Harvey A Whiteford²  Theo Vos¹  Amanda J Baxter²  Rosana Norman³  John J McGrath⁴  Sukanta Saha²  Alize J Ferrari² 

[1] The University of Queensland, School of Population Health, Herston, Queensland, Australia;Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, QLD, Australia;The University of Queensland, Queensland Children’s Medical Research Institute, Herston, QLD, Australia;The University of Queensland, Queensland Brain Institute, St Lucia, QLD, Australia

关键词: Bipolar Disorder;    Schizophrenia;    Health States;    Global Burden of Disease;   

Others  :  806026
DOI  :  10.1186/1478-7954-10-16

 received in 2011-10-06, accepted in 2012-08-10,  发布年份 2012

【 摘 要 】

A comprehensive revision of the Global Burden of Disease (GBD) study is expected to be completed in 2012. This study utilizes a broad range of improved methods for assessing burden, including closer attention to empirically derived estimates of disability. The aim of this paper is to describe how GBD health states were derived for schizophrenia and bipolar disorder. These will be used in deriving health state-specific disability estimates. A literature review was first conducted to settle on a parsimonious set of health states for schizophrenia and bipolar disorder. A second review was conducted to investigate the proportion of schizophrenia and bipolar disorder cases experiencing these health states. These were pooled using a quality-effects model to estimate the overall proportion of cases in each state. The two schizophrenia health states were acute (predominantly positive symptoms) and residual (predominantly negative symptoms). The three bipolar disorder health states were depressive, manic, and residual. Based on estimates from six studies, 63% (38%-82%) of schizophrenia cases were in an acute state and 37% (18%-62%) were in a residual state. Another six studies were identified from which 23% (10%-39%) of bipolar disorder cases were in a manic state, 27% (11%-47%) were in a depressive state, and 50% (30%-70%) were in a residual state. This literature review revealed salient gaps in the literature that need to be addressed in future research. The pooled estimates are indicative only and more data are required to generate more definitive estimates. That said, rather than deriving burden estimates that fail to capture the changes in disability within schizophrenia and bipolar disorder, the derived proportions and their wide uncertainty intervals will be used in deriving disability estimates.

【 授权许可】

   
2012 Ferrari et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Murray CJL, Lopez AD (Eds): The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge; 1996.
• [2]Lopez AD: The evolution of the Global Burden of Disease framework for disease, injury and risk factor quantification: developing the evidence base for national, regional and global public health action. Globalization and Health 2005, 1:1-8. BioMed Central Full Text
• [3]Degenhardt L, Whiteford H, Hall W, Vos T: Estimating the burden of disease attributable to illicit drug use and mental disorders: what is ‘Global Burden of Disease 2005’ and why does it matter? Addiction 2009, 104:1466-1471.
• [4]Mathers CD, Vos ET, Stevenson CE, Begg SJ: The burden of disease and injury in Australia. Bulletin of the World Health Organization vol. 79 edition. 2001, 1076-1084.
• [5]Chisholm D: Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization. World Psychiatry 2005, 4:37-44.
• [6]Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P (Eds): Disease control priorities in developing countries. 2nd edition. Oxford University Press; World Bank, New York; Washington, DC; 2006.
• [7]Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (Eds): In Global Burden of Disease and Risk Factors Disease Control Priorities Project Washington World Bank. 2006.
• [8]Murray CJ, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, Salomon J, Michaud CM, Walker N, Vos T: Global Burden of Disease 2005: call for collaborators. Lancet 2007, 370:109-110.
• [9]Murray CJL, Salomon JA, Mathers C: A critical examination of summary measures of population health. Bulletin of the World Health Organisation 2000, 78:981-994.
• [10]Murray CJL: Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994, 72:429-445.
• [11]Salomon JA, Murray CJ, Ustun B, Chatterji S: Health state valuations in summary measures of population health. In Health systems performance assessment: debates, methods and empiricism. Edited by Murray CJ, Evans DB. World Health Organization, Geneva; 2003:408-436.
• [12]Global Burden of Diseases: Injuries and Risk Factors Study Operations Manual. http://www.globalburden.org/gbdops.html webcite
• [13]Salomon JA: New disability weights for the global burden of disease. Bull World Health Organ 2010, 88:879.
• [14]Crow TJ: Molecular pathology of schizophrenia: more than one disease process? Br Med J 1980, 280:66-68.
• [15]Crow TJ: Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980, 137:383-386.
• [16]Messinger JW, Tremeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D: Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 2011, 31:161-168.
• [17]Faerden A, Friis S, Agartz I, Barrett EA, Nesvag R, Finset A, Melle I: Apathy and functioning in first-episode psychosis. Psychiatr Serv 2009, 60:1495-1503.
• [18]Meltzer HY: Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 1999, 46:1321-1327.
• [19]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Fourth Edition, Text Revision edn edition. American Psychiatric Association, Washington DC; 2000.
• [20]Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS: Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008, 165:978-987.
• [21]World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders, Clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva; 1992.
• [22]Judd LJ, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB: Psychosocial disability in the course of bipolar I and II disorders. Arch Gen Psychiatry 2005, 62:1322-1330.
• [23]Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA 2000, 283:2008-2012.
• [24]Saha S, Chant D, Welham J, McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
• [25]Country and lending groups: Country and lending groups. http://data.worldbank.org/about/country-classifications/country-and-lending-groups webcite
• [26]Soubbotina TP: Comparing levels of development. In Beyond economic growth: An introduction to sustainable development. 2nd edition. World Bank, Washington (DC); 2004:12-15.
• [27]Perera R, Heneghan C: Interpreting meta-analysis in systematic reviews. Evid Based Med 2008, 13:67-69.
• [28]Doi SA, Barendregt JJ, Mozurkewich EL: Meta-analysis Of heterogenous clinical trials: An empirical example. Contemp Clin Trials 2011, 32:288-298.
• [29]Doi SA, Thalib L: A quality-effects model for meta-analysis. Epidemiology 2008, 19:94-100.
• [30]Babigian H: Schizophrenia: Epidemiology. In Comprehensive textbook of psychiatry III. Edited by Kaplan H, Freedman A, Sadock B. Williams & Wilkins, Baltimore/London; 1980:1113-1121.
• [31]Bondestam S, Garssen J, Abdulwakil AI: Prevalence and treatment of mental disorders and epilepsy in Zanzibar. Acta Psychiatr Scand 1990, 81:327-331.
• [32]Fichter MM, Narrow WE, Roper MT, Rehm J, Elton M, Rae DS, Locke BZ, Regier DA: Prevalence of mental illness in Germany and the United States. Comparison of the Upper Bavarian Study and the Epidemiologic Catchment Area Program. J Nerv Ment Dis 1996, 184:598-606.
• [33]Keith S, Regier DA, Rae DS: Schizophrenic disorders. In Psychiatric diseases in America. Edited by Robins LN, Regier DA. Free Press, New York; 1991.
• [34]Shen YC, Zhang WX, Shu L, Yang XL, Cui YH, Zhou DF, Shi HY, Su ET: Investigation of mental disorders in Beijing suburban district. Chinese Medical Journal (Engl) 1981, 94:153-156.
• [35]Zharikov NM: Epidemiological study of mental illness in the U.S.S.R. Soc Psychiatry Psychiatr Epidemiol 1968, 3:135-138.
• [36]Blader JC, Carlson GA: Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996–2004. Biol Psychiatry 2007, 62:107-114.
• [37]Cruz N, Vieta E, Comes M, Haro JM, Reed C, Bertsch J: Rapid-cycling bipolar 1 disorder: Course and treatment outcome of a large sample Europe. J Psychiatr Res 2008, 42:1068-1075.
• [38]Faravelli C, Degl'Innocenti BG, Aiazzi L, Incerpi G, et al.: Epidemiology of mood disorders: A community survey in Florence. J Affect Disord 1990, 20:135-141.
• [39]Have MT, Vollebergh W, Bijl RV, Nolen WA: Bipolar disoder in the general population in the Netherlands (prevalence, consequences and care utilisation): Results from the Netherlands mental health and incidence study (NEMESIS). J Affect Disord 2002, 68:202-213.
• [40]Morgan VA, Mitchell PB, Jablensky AV: The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. Bipolar Disord 2005, 7:326-337.
• [41]Negash A, Alem A, Kebede D, Deyessa N, Shibre T, Kullgren G: Prevalence and clinical characteristics of bipolar I disorder in Butajira, Ethiopia: a community-based study. J Affect Disord 2005, 87:193-201.
• [42]Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon DA, Endicott J, Keller M: Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 2003, 6:127-137.
• [43]Joffe RT, MacQueen GM, Marriott M, Young LT: A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord 2004, 6:62-66.
• [44]Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, Frye MA, Keck PE, McElroy SL, Grunze H, Post RM: Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007, 9:531-535.
• [45]Paykel ES, Abbott R, Morriss R, Hayhurst H, Scott J: Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry 2006, 189:118-123.
• [46]Bonita R, Beaglehole R, Kjellstrom T: Basic epidemiology. 2nd edition. Geneva World Health, Organization; 2006.
• [47]Bromet EJ, Naz B, Fochtmann FJ, Carlson GA, Tanenberg-Karant M: Long-term diagnostic stability and outcome in recent first-episode cohort studies of schizophrenia. Schizophr Bull 2005, 31:639-649.
• [48]Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005, 62:975-983.
• [49]Large M, Farooq S, Nielssen O, Slade T: Relationship between gross domestic product and duration of untreated psychosis in low- and middle-income countries. Br J Psychiatry 2008, 193:227-278.
• [50]Perkins DO, Gu H, Boteva K, Lieberman JA: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005, 162:1785-1804.
• [51]Hopper K, Wanderling J: Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. Schizophr Bull 2000, 26:835-846.
• [52]Cohen A, Patel V, Thara R, Gureje O: Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophr Bull 2008, 34:229-244.
• [53]Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen H: ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 2008, 18:535-549.
• [54]Angst J, Sellaro R: Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000, 48:445-457.